Sarepta (SRPT) Appoints Henri Termeer As Advisor To The Company

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced Henri Termeer, industry leader and former CEO of Genzyme, will be a key advisor to the Company.

"I am honored to have Henri Termeer, a pioneer of rare disease companies, serve as an advisor as we seek FDA approval for our lead product candidate and build a rare disease organization," said Edward Kaye, M.D., Sarepta's interim chief executive officer and chief medical officer.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.